Overview
- Researchers used advanced in vivo imaging in transgenic mice carrying the human HTT mutation to map how different cortical cell types change as Huntington’s disease progresses and identified a marked drop in activity of VIP inhibitory neurons.
- The team applied optogenetics to selectively activate VIP neurons and restored more normal patterns of cortical activity, which improved the mice’s performance on a motor learning task.
- Improvements in circuit function and learning persisted for days after stimulation ended, suggesting the intervention induced lasting plastic changes rather than only brief effects.
- Authors present the work as a proof of concept that targeting a single cell type can 'retune' diseased brain circuits, but they emphasize that optogenetics is an experimental, preclinical tool and has major technical and safety barriers to human use.
- The study reframes Huntington’s research toward circuit-level therapies and points to next steps such as developing noninvasive ways to modulate VIP cells and testing whether similar approaches can help human patients.